Quantcast

Latest Merck Stories

2014-03-07 08:25:14

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding...

2014-03-03 08:30:41

BOSTON, Mar. 3, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee. "Donald Hunter brings a wealth of experience in accounting and control, financial reporting, mergers and...

2014-02-26 12:25:34

Study will use social media to reveal burden, sources and triggers of sleep disorders in the U.S. BOSTON, Feb. 26, 2014 /PRNewswire-USNewswire/ -- Investigators at Boston Children's Hospital and Merck will collaborate on a new study aimed at using social media platforms to better understand insomnia. The researchers aim to contribute new, meaningful information to the scientific community on the predictors of sleep deprivation based on social media-related behaviors, personal online...

2014-02-26 08:27:54

BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Wednesday, March 5, 2014 Time: 8:30...

2014-02-25 08:33:10

PHILADELPHIA, Feb. 25, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced the appointment of Annalisa Jenkins, MBBS, MRCP, Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately. Dr. Jenkins, who previously served as a member of the Board of Directors, will work closely with TransCelerate CEO Dr. Dalvir Gill to...

2014-02-19 23:27:12

AlignLife provides a free webinar to educate on Cholesterol and the risk of statin medications. (PRWEB) February 19, 2014 This Thursday, February 20th at 7pm EST, AlignLife clinics will be hosting a free webinar to educate the community about the dangers of statin medications and a natural approach to the management of cholesterol. An interesting study published in The Lancet looked at the incidence of heart disease in 52 countries and revealed that over 90% of heart disease is...

2014-02-13 23:03:28

A $100 Million NuvaRing Lawsuit Settlement Proposed by Merck & Co. to Settle Thousands of Lawsuits Is Awaiting Approval by 95% of Women Plaintiffs Columbus, OH (PRWEB) February 13, 2014 The NuvaRing attorneys at Wright & Schulte LLC currently representing women in NuvaRing lawsuits is consulting with their clients on whether to agree with the proposed settlement. According to Judge Brian Martinotti, Merck may pay a $100 million settlement to resolve up to 3,800 NuvaRing lawsuits...

2014-02-11 23:28:11

Avail is conducting a randomized, placebo-controlled study to assess the efficacy, long-term safety and tolerability of a new high cholesterol drug in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events. DeLand, FL (PRWEB) February 11, 2014 *To see if you qualify for this High Cholesterol Clinical Study in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to...

2014-02-11 23:26:01

Judge Gives Preliminary Approval of $100 Million To Resolve Thousands of NuvaRing Lawsuits if 95 Percent of Women Agree to Participate New York, NY (PRWEB) February 11, 2014 The lawyers at Alonso Krangle LLP, who are currently representing numerous women in NuvaRing lawsuits, are anticipating Merck, the makers of the NuvaRing contraceptive, will payout out $100 million to settle over 3,800 NuvaRing lawsuits pending in state and federal courts in New Jersey and Missouri (In re: NuvaRing...

2014-02-10 23:26:20

As Bloomberg published on February 8, Merck will pay $100 million to resolve as many as 3,800 lawsuits alleging blood clots from NuvaRing. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of NuvaRing serious complications. San Diego, CA (PRWEB) February 10, 2014 AttorneyOne.com, a recognized authority on law, updated the...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related